نتائج البحث - Freya Droege

  • يعرض 1 - 8 نتائج من 8
تنقيح النتائج
  1. 1
    Prognostic Role of Blood NETosis in the Progression of Head and Neck Cancer

    Prognostic Role of Blood NETosis in the Progression of Head and Neck Cancer حسب Anna Sophie Decker, Ekaterina Pylaeva, Alexandra Brenzel, Ilona Spyra, Freya Droege, Timon Hussain, Stephan Lang, Jadwiga Jabłońska

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets

    Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets حسب Stephan Lang, Kirsten Bruderek, Cordelia Kaspar, Benedikt Höing, Oliver Kanaan, Nina Dominas, Timon Hussain, Freya Droege, Christian Eyth, Boris Hadaschik, Sven Brandau

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    <i>PDCD1</i> (<i>PD-1</i>) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients

    <i>PDCD1</i> (<i>PD-1</i>) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients حسب Diane Goltz, Heidrun Gevensleben, Joern Dietrich, Friederike Schroeck, Luka de Vos, Freya Droege, Glen Kristiansen, Andreas Schroeck, Jennifer Landsberg, Friedrich Bootz, Dimo Dietrich

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT)

    European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT) حسب Claire L. Shovlin, Elisabetta Buscarini, Anette Drøhse Kjeldsen, Hans Jurgen Mager, Carlo Sabbà, Freya Droege, Urban W. Geisthoff, Sara Ugolini, Sophie Dupuis‐Girod

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia

    Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia حسب Claire L. Shovlin, Carolyn M. Millar, Freya Droege, Anette Drøhse Kjeldsen, Guido Manfredi, Patrizia Suppressa, Sara Ugolini, Nicole Coote, Annette Dam Fialla, Urban W. Geisthoff, Gennaro M. Lenato, Hans-Jurgen Mager, Fabio Pagella, Martijn C. Post, Carlo Sabbà, Ulrich Sure, Pernille Mathiesen Tørring, Sophie Dupuis‐Girod, Elisabetta Buscarini

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    European Reference Network for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT)

    European Reference Network for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT) حسب Omer Eker, Edoardo Boccardi, Ulrich Sure, Maneesh C. Patel, Saverio Alicante, Ali Alsafi, Nicole Coote, Freya Droege, Olivier Dupuis, Annette Dam Fialla, Bryony A. Jones, Ujwal Kariholu, Anette Drøhse Kjeldsen, David Lefroy, Gennaro M. Lenato, Hans Jurgen Mager, Guido Manfredi, Troels Halfeld Nielsen, Fabio Pagella, Marco C. Post, Catherine Rennie, Carlo Sabbà, Patrizia Suppressa, Pernille Mathiesen Toerring, Sara Ugolini, Elisabetta Buscarini, Sophie Dupuis‐Girod, Claire L. Shovlin

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    The European Rare Disease Network for HHT Frameworks for management of hereditary haemorrhagic telangiectasia in general and speciality care

    The European Rare Disease Network for HHT Frameworks for management of hereditary haemorrhagic telangiectasia in general and speciality care حسب Claire L. Shovlin, Elisabetta Buscarini, Carlo Sabbà, Hans Jurgen Mager, Anette Drøhse Kjeldsen, Fabio Pagella, Ulrich Sure, Sara Ugolini, Pernille Mathiesen Tørring, Patrizia Suppressa, Catherine Rennie, Martijn C. Post, Mitesh Patel, Troels Halfeld Nielsen, Guido Manfredi, Gennaro M. Lenato, David Lefroy, Ujwal Kariholu, Bryony A. Jones, Annette Dam Fialla, Omer Eker, Olivier Dupuis, Freya Droege, Nicole Coote, Edoardo Boccardi, Ali Alsafi, Saverio Alicante, Sophie Dupuis‐Girod

    منشور في 2021
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    European Reference Network for Rare Vascular Diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)?

    European Reference Network for Rare Vascular Diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)? حسب Sophie Dupuis‐Girod, Claire L. Shovlin, Anette Drøhse Kjeldsen, Hans‐Jurgen Mager, Carlo Sabbà, Freya Droege, Anne‐Emmanuelle Fargeton, Annette Dam Fialla, S. Gandolfi, Ruben Hermann, Gennaro M. Lenato, Guido Manfredi, Marco C. Post, Catherine Rennie, Patrizia Suppressa, Ulrich Sure, Elisabetta Buscarini, Claudia Crocione, Ria Blom, Luisa M. Botella, Fernando Brocca, Caroline Coxall, Karen T. Druckman, Didier Erasme, Paolo Roberto Federici, Christina Grabowski, Mildred Lundgren, Tone Søderman, Dara Woods

    منشور في 2022
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: